SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole
for patients switched from pramipexole to ropinirole in patients with moderate to severe
primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with
Restless Legs Syndrome can maintain stable efficacy and tolerability if correctly switched
from one dopamine agonist to an equipotent dose of another.